ESSA Pharma (NASDAQ:EPIX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) announced its quarterly earnings data on Tuesday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01), Zacks reports.

ESSA Pharma Price Performance

NASDAQ EPIX opened at $1.61 on Wednesday. The company has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $3.67. ESSA Pharma has a 52-week low of $1.40 and a 52-week high of $10.94.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Piper Sandler downgraded shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $15.00 to $2.00 in a research note on Monday, November 4th. Jefferies Financial Group cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, Oppenheimer cut shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.